Last reviewed · How we verify
Chewing Ticagrelor
At a glance
| Generic name | Chewing Ticagrelor |
|---|---|
| Sponsor | Sheba Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Chewed Versus Integral Pill of Ticagrelor (PHASE4)
- Pharmacodynamic Evaluation of Antiplatelet Effect of Swallowing Versus Chewing Ticagrelor in Patients With Acute Coronary Syndrome (PHASE4)
- Cangrelor vs. Ticagrelor for Early Platelet Inhibition in STEMI (PHASE4)
- Chewing Ticagrelor Versus Prasugrel in ST-elevation Myocardial Infarction - A Platelet Reactivity Study (PHASE4)
- Chewing Versus Traditional Oral Administration of Ticagrelor in STEMI Patients (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Chewing Ticagrelor CI brief — competitive landscape report
- Chewing Ticagrelor updates RSS · CI watch RSS
- Sheba Medical Center portfolio CI